Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.58 |
| ▸ | HTR2A | P28223 | 11/20 | 0.58 |
| ▸ | DRD2 | P14416 | 7/20 | 0.55 |
| ▸ | DRD1 | P21728 | 6/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22118531 | 1.00 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL21699949 | 1.00 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL29456967 | 1.00 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL22118530 | 1.00 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL30641165 | 1.00 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL31659338 | 1.00 | OPRM1 (0.58) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL31150371 | 0.93 | OPRM1 (0.55) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL5506007 | 0.86 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL22023339 | 0.86 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 | |
| SCHEMBL30579711 | 0.86 | OPRM1 (0.60) | OPRM1HTR2ADRD2DRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | claimed |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260041684-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3898581-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12297200-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250099471-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240415832-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-12-19 | — | — | US | disclosed |
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-07-06 | — | — | US | disclosed |
| US-7071186-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1189904-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | ROBICHAUD ALBERT J (US) | 2004-02-19 | — | — | US | disclosed |
| US-6552017-B1 | As serotonin agonists and antagonists and are useful in the control or prophylaxis of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358916-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | OPRM1 967/4885HTR2A 1243/4885DRD2 221/4885 |
| US-20040034015-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | OPRM1 19/4885HTR2A 30/4885DRD2 16/4885 |
| US-20060148808-A1 | Substituted heterocycle fused gamma-carbolines | HTR2B, HTR1B, HTR3B | OPRM1 39/4885HTR2A 17/4885DRD2 11/4885 |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | OPRM1 626/4885HTR2A 317/4885DRD2 483/4885 |
| US-20240415832-A1 | NOVEL METHODS | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885HTR2A 703/4885DRD2 258/4885 |
| US-20250099471-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR1A | OPRM1 34/4885HTR2A 2/4885DRD2 17/4885 |
| US-20260041684-A1 | ORGANIC COMPOUNDS | OPRD1, DRD2, HTR2C | OPRM1 4/4885HTR2A 15/4885DRD2 2/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | OPRM1 19/4885HTR2A 30/4885DRD2 16/4885 |
| US-20260098040-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | KCNH2, KCNH3, KCNH1 | OPRM1 923/4885HTR2A 3077/4885DRD2 660/4885 |
| US-12297200-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | OPRM1 967/4885HTR2A 1243/4885DRD2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.